Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

Among persons with residual invasive disease after treatment of HER2-positive early breast cancer, trastuzumab emtansine resulted in 7-year invasive disease–free survival of 80.8%, as compared with 67.1% with trastuzumab.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology